lung cancer

Authors and Affiliations:

Flávia Pereira ^1,2,3,4, Anabela Ferreira ^1,2, Celso Albuquerque Reis ^3,5,6, Maria João Sousa ^1,2, Maria José Oliveira ^3,4,5 and Ana Preto ^1,2

¹ Centre of Molecular and Environmental Biology (CBMA), Department of Biology, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal

The presence of polymorphic gene variants in the human genome provides extensive genetic (and eventually phenotypic) variation affecting both normal physiological mechanisms and cancer pathogenesis. Functional genetic polymorphisms might have predictive and/or prognostic value in lung cancer, opening novel opportunities to improve prediction and guide clinical reasoning and therapeutics in lung cancer patients.

Virtual event, Worldwide

23 - 24 March, 2020

See more informations here: https://www.eacr.org/conference/molecularpathology2021virtual?utm_source=confseriespage&utm_medium=web&utm_campaign=vMP21&utm_content=

Virtual event, Worldwide

23 - 24 March, 2021

See more informations here: https://www.eacr.org/conference/molecularpathology2021virtual?utm_source=confseriespage&utm_medium=web&utm_campaign=vMP21&utm_content=

Authors and Affiliations:

Ana Raquel-Cunha ^1,2, Diana Cardoso-Carneiro ^1,2, Rui M. Reis ^1,2,3 and Olga Martinho ^1,2,3*

1- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal;

2 - ICVS/3Bs-PT Government Associate Laboratory, Braga/Guimarães, Portugal;

3 - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

Abstract:

A equipa liderada por Olga Martinho, do Instituto de Investigação em Ciências da Vida e Saúde (ICVS) da Universidade do Minho, focou esta revisão no estado da arte sobre a proteína RKIP em cancro do pulmão, tendo apresentando ainda alguns dados originais resultantes de uma análise in silico usando a base de dados do TCGA.  A proteína inibidora da quinase RAF1 (RKIP) é uma importante moduladora de vias de sinalização intracelular relevantes, incluindo aquelas controladas pelo EGFR, como a via das MAPK.

The discovery of crucial misexpressed genes in lung cancer allows a better understanding about the tumor microenvironment and the biomarkers that are a genetic fingerprint of this cancer. These biomarkers provide relevant knowledge to start the development of targeted therapies, overcoming the side effects and the development of resistances associated with the conventional treatments. Gene therapy and RNAi-based drugs are pointed out as promising and exciting new approaches to treat lung cancer.

A descoberta de genes cruciais e mal-expressos no cancro de pulmão permite um melhor entendimento do microambiente do tumor e dos biomarcadores que são uma impressão genética desse cancro. Esses biomarcadores fornecem um conhecimento relevante para iniciar o desenvolvimento de terapias direcionadas, superando os efeitos colaterais e o desenvolvimento de resistências associadas aos tratamentos convencionais. A terapia génica e os medicamentos baseados em RNAi são apontados como novas e promissoras abordagens para o tratamento do cancro de pulmão.